Since I've dropped by to mention when I've sold out of SNMX in the past, I figured I should also mention that I have re-accumulated an overweight position in the name. Now has <$50m enterprise value.
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.